Advertisement

Effect of Antithrombin III Concentrate for DIC in Obstetrics and Gynecology

The Changes of Prostanoids in Plasma Before and After Administration
  • Hiroshi Suzuki
  • Mayumi Kasai
  • Ken Satoh
  • Hajime Iida
  • Hiroki Suzuki
  • Iwao Nishiya
Conference paper

Abstract

Obstetrical disseminated intravascular coagulation (DIC) is frequently acute and sometimes life threatening. However, early diagnosis and prompt treatment often save lives. We have shown in patients with gestosis that changes in vasoactive substances such as prostaglandin and prostanoid are associated with progression of the disease that induces chronic DIC [1–3]. On the other hand, DIC complicating gynecological malignant tumors are mostly seen at the terminal stage of the disease, and, therefore, active treatment for DIC has been rarely performed. However, recent advances in the anti-cancer therapy and radiotherapy for gynecological malignant tumors have prolonged the life of some patients. During chemotherapy with anti-cancer drugs, DIC sometimes develops, and active treatment for DIC is often required. In this study, we administered an antithrombin III concentrate (AT-III) to 7 patients with obstetric DIC and 10 of 15 patients treated for gynecological malignant tumors who had DIC or were expected to develop DIC. To evaluate the usefulness of this drug, the AT-III activity and various effects, especially on prostanoid, were studied.

Keywords

Disseminate Intravascular Coagulation Disseminate Intravascular Coagulation Drip Infusion Fibrinogen Degradation Product Iwate Prefectural 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Suzuki H (1979) Studies on the clinical significance of plasma prostaglandin F2 α and prostaglandin F2 α -main-urinary-metabolite. Acta Obstet Gynaecol Jpn 31: 87Google Scholar
  2. 2.
    Tsukatani E (1983) Etiology of EPH-gestosis from the viewpoint of dynamics of vasoactive prostanoid, lipid peroxides and vitamin E. Acta Obstet Gynaecol Jpn 35: 713Google Scholar
  3. 3.
    Omi K (1986) Changes in endogenous prostaglandin and affinous substances in gestosis. J Iwate Med Assoc (Morioka) 38: 67Google Scholar
  4. 4.
    Maki M, Terao T, Ikenoue K (1985) Obstetrical DIC score (in Japanese). Obstet Gynecol Ther (Tokyo) 50: 119Google Scholar
  5. 5.
    Research Group for Blood Coagulation Abnormalities (1986) In: Kobayashi N (ed) Specified diseases research report, vol 47 (in Japanese). Ministry of Public Welfare, TokyoGoogle Scholar
  6. 6.
    Suzuki H, Saito K, Adachi N, Kasai M, Haga K, Tsukatani E, Ito K, Kunimoto K, Nishitani I (1987) Effects of antithrombin III concentrates on obstetrical DIC: Changes in blood prostanoid after administration (in Japanese). Obstet Gynecol (Tokyo) 54: 1219Google Scholar
  7. 7.
    Suzuki H, Kasai M, Harada K, Iida H (1987) Effect of antithrombin on obstetrical and gynaecological DIC (in Japanese). J Iwate Pref Hosp Assoc (Morioka) 27: 48Google Scholar
  8. 8.
    Nakabayashi M, Chin Z, Takeda S, Baba K, Kinoshita K, Kawana H, Sato K, Mizuno M (1984) Antifibrinolytic therapy for the ascites ovarian cancer (in Japanese). Obstet Gynecol (Tokyo) 10: 1409Google Scholar
  9. 9.
    Shinagawa N, Kagiya A, Tominra K, Takano A (1984) Gynecological malignant tumor: Diagnosis and treatment of DIC (in Japanese). Gendaiiryosha, Tokyo, pp 262–269Google Scholar
  10. 10.
    Suzuki H, Kasai M, Kubota T, Harada K, Iida H (1988) Effect on antithrombin III concentrates for DIC in gynaecological malignant tumor (in Japanese). Obstet Gynecol (Tokyo) 55: 489Google Scholar
  11. 11.
    Thalar E (1982) Antithrombin III-Konzentrate Klinische Anwendung. Hamostaseologie 3: 128Google Scholar
  12. 12.
    Takahashi K (1980) Studies on antithrombin III. II. The role for antithrombin HI (AT III) in the control of disseminated intravascular coagulation (DIC). The effect of the administration of AT III concentrates in experimental DIC and in clinical DIC. Acta Haematol Jpn 43: 889Google Scholar
  13. 13.
    Samuelsson B (1976) Introduction: New trends in prostaglandin research. In: Samuels-son B, Paoletti R (eds) Advances in prostaglandin and thromboxane research, vol 1. Raven Press, New YorkGoogle Scholar
  14. 14.
    Moncada S, Gryglewski R, Bunting S, Vane JR (1976) An enzyme isolated from artteries transforms prostaglandin endperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1991

Authors and Affiliations

  • Hiroshi Suzuki
    • 1
  • Mayumi Kasai
    • 1
  • Ken Satoh
    • 1
  • Hajime Iida
    • 1
  • Hiroki Suzuki
    • 2
  • Iwao Nishiya
    • 2
  1. 1.Department of Obstetrics and GynecologyIwate Prefectural Central HospitalMorioka, 020Japan
  2. 2.Department of Obstetrics and GynecologyIwate Medical UniversityMorioka, 020Japan

Personalised recommendations